- Home
- CTO vs ORIC Comparison
CTO vs ORIC Comparison
Compare CTO & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTO | ORIC |
|---|---|---|
| Founded | 1902 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 776.3M | 1.4B |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CTO | ORIC |
|---|---|---|
| Price | $20.77 | $11.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 16 |
| Target Price | ★ $24.60 | $21.43 |
| AVG Volume (30 Days) | 372.7K | ★ 1.5M |
| Earning Date | 10-27-2026 | 11-12-2026 |
| Dividend Yield | ★ 7.31% | N/A |
| EPS Growth | ★ 122.86 | 19.67 |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $149,545,000.00 | N/A |
| Revenue This Year | $18.22 | N/A |
| Revenue Next Year | $9.81 | N/A |
| P/E Ratio | $159.92 | ★ N/A |
| Revenue Growth | ★ 20.10 | N/A |
| 52 Week Low | $15.59 | $7.23 |
| 52 Week High | $22.71 | $14.68 |
Technical Indicators
Market Signals| Indicator | CTO | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 51.49 | 32.65 |
| Support Level | $19.87 | $10.17 |
| Resistance Level | $20.86 | $12.59 |
| Average True Range (ATR) | 0.35 | 0.69 |
| MACD | 0.08 | -0.17 |
| Stochastic Oscillator | 79.01 | 11.44 |
Price Performance
Historical ComparisonAbout CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties in diversified markets in the United States. The company operates in four primary business segments: Income properties, management services, commercial loans and investments, and real estate operations. It derives maximum revenue from Income Properties.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.